Cynthia A. Challener

The best strategy is to use a combination of complementary methods.

Weighing development costs/resources and performance benefits is essential.

Collaboration between technology providers and biopharma manufacturers are enabling both evolutionary and novel developments.

Platform processes and effective risk assessments help overcome time and cost challenges.

Gamma irradiation is being supplemented with alternative technologies.

Using a multi-pronged strategy to find optimum, tailored formulations is best.

Sterile filtration and use of sterile single-use materials provide the best solutions depending on vector size.

Increases in efficiencies, flexibility, scalability, and sustainability are impacting adoption.

Proprietary cell lines offer opportunities for achieving high AAV titers.

Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.

Developing freeze-drying processes requires patience and deep product and process understanding.

Product and process understanding are essential to effective resin selection.

A look at how linker technology for antibody drug conjugates has evolved.

Preparing for variability and flexible processing are necessary for success.

There is no such thing as a perfect linker.

Using a systematic approach and achieving run-to-run consistency are essential.

Process and bioreactor performance are directly impacted by real-time monitoring capabilities.

Stable producer cell lines show real promise despite continued development challenges.

Sourcing of donor cells, access to fit-for-purpose reagents and manufacturing systems, and scalability are top issues.

Despite many development challenges, stable producer cell lines show real promise.

When one is using continuous hot-melt extrusion to enhance solubility, process control is essential.

Media developers and vector manufacturers face a combination of challenges and opportunities.

Batch-to-batch variability and impurities present critical challenges.

Optimization strategies that leverage advanced technologies are essential for maximizing yield and quality.

Stability and in vivo performance aren't just affected by lipids.

The breakthrough approach is commonly used, but the devil is in the details.

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.

Process and plasmid design optimization, disposable equipment, and flexible platform processes all play important roles.

In vivo CAR-T gene therapies could overcome the challenges faced by autologous and allogeneic treatments.

Messenger RNA is inherently unstable and thus requires unique solutions to protect its cohesion.